Literature DB >> 9508371

Expression of MAGE, gp100 and tyrosinase genes in uveal melanoma cell lines.

G P Luyten1, C W van der Spek, I Brand, K Sintnicolaas, I de Waard-Siebinga, M J Jager, P T de Jong, P I Schrier, T M Luider.   

Abstract

In order to determine the possible use of uveal melanoma cell lines as stimulators in immunotherapy, we evaluated the expression of the human genes for MAGE-1, -2 and -3, gp100 and tyrosinase in uveal melanoma cell lines. mRNA expression of the MAGE-1, -2 and -3, gp100 and tyrosinase genes and the HLA class I specificity were determined in five primary and three metastatic uveal melanoma cell lines. Expression of the examined genes was heterogeneous in the primary and metastatic cell lines. The cell lines OCM-1 and OMM-1 expressed MAGE-1, -2 and -3, whereas EOM-3, MEL202, 92-1 and OMM-3 were negative for these antigens. gp100 was expressed in all cell lines, and tyrosinase in all but three (EOM-29, OMM-2 and OMM-3). Except for EOM-3, the HLA-A type of all the cell lines could be determined by complement-dependent microlymphocytotoxicity assay. Since at least two melanoma-associated antigens can be found in uveal melanoma cell lines, as well as the HLA class I molecules, these cell lines may be applicable as immunogens for specific immunotherapy against metastatic uveal melanoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9508371     DOI: 10.1097/00008390-199802000-00003

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  10 in total

Review 1.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

Review 2.  Biology of advanced uveal melanoma and next steps for clinical therapeutics.

Authors:  Jason J Luke; Pierre L Triozzi; Kyle C McKenna; Erwin G Van Meir; Jeffrey E Gershenwald; Boris C Bastian; J Silvio Gutkind; Anne M Bowcock; Howard Z Streicher; Poulam M Patel; Takami Sato; Jeffery A Sossman; Mario Sznol; Jack Welch; Magdalena Thurin; Sara Selig; Keith T Flaherty; Richard D Carvajal
Journal:  Pigment Cell Melanoma Res       Date:  2014-09-01       Impact factor: 4.693

Review 3.  Uveal Melanoma Cell Lines: Where do they come from? (An American Ophthalmological Society Thesis).

Authors:  Martine J Jager; J Antonio Bermudez Magner; Bruce R Ksander; Sander R Dubovy
Journal:  Trans Am Ophthalmol Soc       Date:  2016-08

Review 4.  The Silver locus product Pmel17/gp100/Silv/ME20: controversial in name and in function.

Authors:  Alexander C Theos; Steven T Truschel; Graça Raposo; Michael S Marks
Journal:  Pigment Cell Res       Date:  2005-10

5.  Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.

Authors:  Jason J Luke; Margaret K Callahan; Michael A Postow; Emanuela Romano; Nikhil Ramaiya; Mark Bluth; Anita Giobbie-Hurder; Donald P Lawrence; Nageatte Ibrahim; Patrick A Ott; Keith T Flaherty; Ryan J Sullivan; James J Harding; Sandra D'Angelo; Mark Dickson; Gary K Schwartz; Paul B Chapman; Jedd D Wolchok; F Stephen Hodi; Richard D Carvajal
Journal:  Cancer       Date:  2013-08-02       Impact factor: 6.860

Review 6.  HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target.

Authors:  Zahra Souri; Annemijn P A Wierenga; Arend Mulder; Aart G Jochemsen; Martine J Jager
Journal:  Cancers (Basel)       Date:  2019-08-07       Impact factor: 6.639

Review 7.  The Role of Immune Checkpoint Blockade in Uveal Melanoma.

Authors:  Anja Wessely; Theresa Steeb; Michael Erdmann; Lucie Heinzerling; Julio Vera; Max Schlaak; Carola Berking; Markus Vincent Heppt
Journal:  Int J Mol Sci       Date:  2020-01-29       Impact factor: 5.923

Review 8.  How to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma.

Authors:  Mariarosaria Marseglia; Adriana Amaro; Nicola Solari; Rosaria Gangemi; Elena Croce; Enrica Teresa Tanda; Francesco Spagnolo; Gilberto Filaci; Ulrich Pfeffer; Michela Croce
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

9.  Interplay between TERT promoter mutations and methylation culminates in chromatin accessibility and TERT expression.

Authors:  Catarina Salgado; Celine Roelse; Rogier Nell; Nelleke Gruis; Remco van Doorn; Pieter van der Velden
Journal:  PLoS One       Date:  2020-04-08       Impact factor: 3.240

Review 10.  Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets.

Authors:  Maria Sofia Basile; Emanuela Mazzon; Paolo Fagone; Antonio Longo; Andrea Russo; Matteo Fallico; Vincenza Bonfiglio; Ferdinando Nicoletti; Teresio Avitabile; Michele Reibaldi
Journal:  Front Oncol       Date:  2019-11-05       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.